Litigation Details for Mallinckrodt LLC v. Taro Pharmaceutical Industries Ltd. (D. Del. 2013)

Mallinckrodt LLC v. Taro Pharmaceutical Industries Ltd. (D. Del. 2013)

Docket		Date Filed	2013-03-28
Court	District Court, D. Delaware	Date Terminated	2014-10-06
Cause	35:0145	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	8,217,078
Link to Docket	External link to docket

Details for Mallinckrodt LLC v. Taro Pharmaceutical Industries Ltd. (D. Del. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-03-28				External link to document

Mallinckrodt LLC v. Taro Pharmaceutical Industries Ltd. Litigation Summary and Patent Analysis

Last updated: August 3, 2026

Mallinckrodt LLC v. Taro Pharmaceutical Industries Ltd., No. 1:13-cv-00494, was a Hatch-Waxman patent dispute in the U.S. District Court for the District of Delaware involving Taro's abbreviated new drug application for a generic version of Mallinckrodt's Ofirmev, an injectable acetaminophen product. Mallinckrodt asserted U.S. Patent Nos. 6,028,222 and 6,992,096. The case was resolved without a public merits judgment, and the public docket does not disclose the commercial terms of the parties' resolution. [1]

The dispute was commercially important because Ofirmev was a branded intravenous acetaminophen product with hospital use and limited early competition. The asserted patents have since expired, eliminating the historical patent barrier. The case involved a small-molecule generic under the ANDA pathway, not a biologic or biosimilar application.

What drug and patents were at issue in Mallinckrodt v. Taro?

The litigation concerned Ofirmev, an intravenous formulation of acetaminophen. Mallinckrodt marketed Ofirmev for the management of mild-to-moderate pain and moderate-to-severe pain as an adjunct to opioid analgesics, and for reduction of fever in adults and children. [2]

Taro's ANDA sought FDA approval to market a generic injectable acetaminophen product. Mallinckrodt filed suit after receiving Taro's Paragraph IV certification that the relevant Orange Book patents were invalid, unenforceable, or would not be infringed.

Item	Detail
Brand product	Ofirmev
Active ingredient	Acetaminophen
Dosage form	Intravenous injection
Regulatory pathway	ANDA under Hatch-Waxman
Plaintiff	Mallinckrodt LLC
Defendant	Taro Pharmaceutical Industries Ltd.
Court	U.S. District Court for the District of Delaware
Case number	1:13-cv-00494
Filed	2013
Patent numbers	U.S. Patent Nos. 6,028,222 and 6,992,096
Disposition	Resolved without a public merits judgment

What patents protected Ofirmev in the Taro litigation?

Mallinckrodt asserted two patents directed to acetaminophen injection technology.

U.S. Patent No. 6,028,222

The '222 patent covered acetaminophen compositions for injection. Its subject matter was directed to an injectable formulation designed to provide a usable acetaminophen product for intravenous administration.

The patent was central to Ofirmev's original patent protection. Its term expired before the end of the decade following the litigation, subject to any applicable patent-term adjustment or extension reflected in the official patent and Orange Book records.

U.S. Patent No. 6,992,096

The '096 patent also concerned acetaminophen compositions and injectable pharmaceutical formulations. The patent provided a later layer of protection around the product and formulation technology.

The two patents gave Mallinckrodt more than a single composition patent. They created overlapping protection around the injectable product, which increased the cost and uncertainty of an early generic challenge. The litigation record, however, does not establish that either patent survived a final validity or infringement determination against Taro.

When did the Ofirmev patents expire?

The '222 and '096 patents have expired. The relevant patent terms were materially earlier than the extended commercial life of Ofirmev.

Patent	General subject matter	Approximate statutory expiration	Current status
U.S. 6,028,222	Acetaminophen injectable compositions	2017, subject to applicable term adjustments	Expired
U.S. 6,992,096	Acetaminophen formulation technology	2022, subject to applicable term adjustments	Expired

The precise enforceable expiration date must be determined from the issued patent record, any patent-term adjustment, any patent-term extension, and the FDA Orange Book listing applicable to the approved product. The patents no longer create a current U.S. patent barrier to an ANDA applicant.

What was Taro's Paragraph IV challenge?

Taro's ANDA filing triggered the Hatch-Waxman litigation. A Paragraph IV certification alleges that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. [3]

Mallinckrodt's lawsuit followed the Paragraph IV notice. Filing the action within the statutory period generally creates a 30-month stay of FDA approval, unless the litigation is resolved earlier or the court modifies the stay. The case therefore had two immediate effects:

1. It delayed potential FDA approval of Taro's generic product.
2. It required Mallinckrodt to defend the validity and scope of the Ofirmev patent estate.

The public docket does not show a final opinion determining whether Taro's proposed product would infringe the asserted claims. It also does not show a trial verdict invalidating or upholding the patents.

How was Mallinckrodt v. Taro resolved?

The case was resolved through a negotiated disposition rather than a public merits ruling. The docket reflects termination of the action without a reported judgment on patent validity or infringement. [1]

The public court record does not disclose the material commercial terms of the resolution. As a result, the record does not establish:

• Taro's authorized launch date;
• whether Taro received a license;
• whether the agreement contained a launch date, royalty, or supply provision;
• whether Taro agreed to an authorized-generic arrangement;
• whether Mallinckrodt imposed manufacturing or distribution restrictions.

A confidential settlement does not establish that the asserted patents were strong or weak. It indicates that the parties allocated litigation and launch risk through a private agreement.

What was the Orange Book status of Ofirmev?

Ofirmev was subject to Orange Book-listed patent protection during the period of the Taro litigation. The relevant listings supported Mallinckrodt's use of the Hatch-Waxman framework to challenge Taro's ANDA. [4]

The Orange Book listings were commercially significant because they provided the legal basis for a Paragraph IV certification and the potential 30-month approval stay. They did not guarantee that the patents would survive litigation. Orange Book listing is an administrative and regulatory status, not a judicial determination of patent validity.

Current commercial analysis differs from the analysis at filing:

Issue	Status during 2013 litigation	Current significance
Orange Book patents	Active listings supported Hatch-Waxman suit	Listed patents have expired
30-month stay	Potentially delayed FDA approval	No longer relevant to these patents
Paragraph IV risk	Material litigation exposure	Historical only
Generic entry	Dependent on settlement and FDA approval	Patent-based entry barrier removed
Patent exclusivity	Supported Ofirmev's early market position	Ended after patent expiration

Regulatory exclusivity and patent exclusivity must be separated. FDA market exclusivity, if any, is distinct from the patent terms and does not revive expired patents.

What formulation patents protected injectable acetaminophen?

The case involved formulation protection rather than a conventional small-molecule active-ingredient patent. Acetaminophen itself is an old active ingredient. The commercial value of the asserted estate came from the injectable dosage form and the technical requirements for producing a stable intravenous formulation.

Formulation patents can remain commercially relevant even when the active ingredient is off patent. Their value depends on claim scope. Broad claims covering the active ingredient and essential excipients can create meaningful barriers. Narrow claims tied to particular concentration ranges, impurity limits, solvents, or manufacturing conditions are easier for a generic applicant to design around.

For Ofirmev, the principal patent risk was therefore product-specific:

• whether Taro's formulation fell within the asserted composition claims;
• whether the proposed product used the claimed formulation parameters;
• whether the patent claims were enabled and nonobvious;
• whether prior art disclosed comparable injectable acetaminophen compositions;
• whether Taro's ANDA product could be approved without practicing the claimed technology.

The absence of a merits decision means the public record does not quantify the strength of any individual claim.

How strong was Mallinckrodt's Ofirmev patent estate?

The estate was commercially useful but not demonstrably litigation-proven in the Taro case.

Strengths

The estate had several practical advantages:

• It covered a marketed injectable product rather than an uncommercialized research formulation.
• It used more than one patent to protect the product.
• The patents were listed in the Orange Book.
• A Paragraph IV filing created immediate regulatory and litigation consequences.
• Hospital injectable products can present manufacturing, quality, and supply-chain barriers that complement patent protection.

Limitations

The estate also had structural limitations:

• Acetaminophen was a well-established active ingredient.
• The patents were formulation-focused, making claim construction and design-around arguments important.
• The patents had finite remaining terms when the case was filed.
• The public docket contains no final infringement or validity ruling.
• Expiration removed the legal barrier even if the product retained commercial advantages.

The strongest conclusion supported by the record is that Mallinckrodt had sufficient patent and regulatory leverage to litigate and negotiate, but the Taro case does not provide a judicial validation of the patent estate.

Did the case involve biosimilar risk?

No. Taro's proposed product was a generic small-molecule injectable acetaminophen product submitted through an ANDA. Biosimilar approval under the Public Health Service Act was not involved. [3]

This distinction matters for competitive analysis. A generic applicant must generally demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy the applicable ANDA requirements. A biosimilar applicant instead relies on a reference biological product and faces a different scientific, regulatory, and interchangeability framework.

The relevant competitive risks were therefore:

• Paragraph IV patent litigation;
• formulation design-around;
• FDA approval timing;
• manufacturing compliance;
• hospital contracting;
• injectable-product supply reliability.

Which companies challenged Ofirmev patents?

Mallinckrodt's Ofirmev patent estate attracted generic interest because intravenous acetaminophen had an established hospital market and could be substituted through the ANDA pathway. The Taro action was one of several disputes involving generic applicants and Ofirmev-related patent protection.

The relevant competitive group included generic injectable manufacturers and distributors capable of producing acetaminophen injection at commercial scale. Taro's participation demonstrated that the market was open to generic challenge before expiration of the asserted patents.

The competitive threat was more constrained than in a mass-market oral tablet because injectable products require:

• sterile manufacturing capacity;
• FDA-compliant facilities;
• reliable vial or bag production;
• hospital supply contracts;
• controls for particulate and endotoxin contamination;
• inventory and shortage management.

These manufacturing barriers could delay or limit practical competition even after patent-based entry became available.

What patent litigation affected Ofirmev generic entry?

The principal effect of the case was timing. Mallinckrodt's complaint invoked the statutory litigation stay and prevented immediate FDA approval while the patent dispute remained active or until the parties resolved it.

The case did not produce a published decision setting a generic launch date. A confidential resolution could have permitted an agreed entry date earlier than patent expiration, but the public docket does not disclose that date.

A generic launch analysis must therefore distinguish three dates:

Date type	Meaning
Patent expiration	End of enforceable patent rights
FDA approval date	Date the agency could approve the ANDA
Commercial launch date	Date the generic actually entered the market

These dates often differ. FDA approval may occur before patent expiration if an agreement permits entry. Commercial launch may occur later because of manufacturing, supply, pricing, or contracting considerations.

What revenue exposure did the litigation create for Mallinckrodt?

The case threatened a branded injectable product with hospital and procedural use. Generic entry could have reduced Ofirmev's price, unit volume, formulary position, or contracting leverage.

Revenue exposure depended on:

• Ofirmev's annual sales at the time;
• the number of approved generic competitors;
• the negotiated launch date;
• generic pricing discounts;
• hospital purchasing behavior;
• the availability of therapeutic alternatives;
• manufacturing capacity among generic suppliers.

Patent litigation was only one part of the commercial defense. Mallinckrodt also had to preserve product differentiation, maintain supply reliability, and manage hospital accounts. Injectable products may experience slower generic substitution than oral products, but they remain exposed to group purchasing organization pressure and formulary economics.

What generic launch risks existed after the settlement?

After resolution, the principal risks shifted from patent liability to execution and market access.

Regulatory risk

Taro still needed FDA approval of its ANDA and satisfaction of chemistry, manufacturing, and controls requirements. A patent settlement would not itself guarantee approval.

Manufacturing risk

Sterile injectable production is operationally demanding. Batch failures, inspection findings, container-closure issues, or supply interruptions could delay launch.

Commercial risk

Taro would have faced competition from other generic injectable manufacturers. A first entrant can obtain an early pricing advantage, but the advantage may narrow rapidly as additional ANDAs receive approval.

Litigation risk

A settlement may resolve the claims between the named parties without eliminating disputes involving other generic applicants. Other manufacturers could continue challenging the same patents or launch after expiration.

How does the Taro case compare with a typical Hatch-Waxman patent dispute?

The case followed a conventional pattern:

1. Mallinckrodt obtained FDA approval for a branded product.
2. Patents covering the product were listed in the Orange Book.
3. Taro filed an ANDA with a Paragraph IV certification.
4. Mallinckrodt sued in the District of Delaware.
5. The litigation created a potential 30-month approval stay.
6. The parties resolved the case without a public merits judgment.

The unusual feature from an evidentiary perspective is the absence of a reported opinion establishing claim construction, infringement, validity, or enforceability. Investors and competitors should not treat the settlement as a binding assessment of the patents.

Key Takeaways

• Mallinckrodt sued Taro in 2013 over an ANDA for generic Ofirmev, an injectable acetaminophen product.
• The asserted patents were U.S. Patent Nos. 6,028,222 and 6,992,096.
• The case was a Hatch-Waxman Paragraph IV dispute involving a small-molecule generic, not a biosimilar.
• The action ended without a public merits decision on infringement or validity.
• The settlement terms and any agreed Taro launch date were not publicly disclosed in the court record.
• The asserted patent estate has expired, so it no longer blocks U.S. generic entry.
• Manufacturing, FDA approval, sterile production, and hospital contracting remain separate commercial issues from patent protection.

Frequently Asked Questions

Did Taro win or lose Mallinckrodt v. Taro?

Neither outcome is established by a public merits judgment. The case was resolved without a reported decision holding that Taro infringed or that Mallinckrodt's patents were invalid.

Was Ofirmev protected by a method-of-use patent?

The Taro case centered on patents directed to acetaminophen injectable compositions and formulation technology. The public record does not establish a final ruling on any separate method-of-use theory against Taro.

Could Mallinckrodt sue another generic after settling with Taro?

Yes. A settlement with one ANDA applicant would not automatically resolve claims against unrelated generic applicants. Each applicant's product and patent certifications would require separate analysis.

Are the Ofirmev patents still enforceable?

The patents asserted in the case have expired. They no longer provide an active U.S. patent exclusion against generic injectable acetaminophen products.

Is the Taro case relevant to current biosimilar litigation?

No. The case involved an ANDA for a small-molecule injectable drug. Its procedural and regulatory framework is different from biosimilar litigation under the Public Health Service Act.

References

1. U.S. District Court for the District of Delaware. (2013). Mallinckrodt LLC v. Taro Pharmaceutical Industries Ltd., No. 1:13-cv-00494, docket materials.

2. U.S. Food and Drug Administration. (n.d.). Ofirmev acetaminophen injection prescribing information. FDA.

3. U.S. Food and Drug Administration. (2017). Abbreviated new drug application regulations and patent certifications. FDA.

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.